The association of centromere amplification and response to trastuzumab in HER2+metastatic breast cancer

被引：0
|
作者：
Andrieu, Charlotte
Al-Sultan, Dalal
Ivers, Laura
Pina, Jose Javier Berenguer
Skrobo, Darko
Ballot, Josephine
Eustace, Alex J.
Gullo, Giuseppe
Crown, John
机构：
[1] Dublin City Univ, Sch Biotechnol, Natl Inst Cellular Biotechnol, Dublin, Ireland
[2] St Vincents Univ Hosp, Dept Med Oncol, Dublin, Ireland
[3] CCRT Caroline Fdn, Dublin, Ireland
[4] Galway Univ Hosp, Dept Histopathol, Galway, Ireland
[5] St Vincents Univ Hosp, Dept Med Oncol, Dublin, Ireland
[6] St Vincents Univ Hosp, Dept Pathol, Dublin, Ireland
[7] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1016
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of pertuzumab in HER2+metastatic breast cancer
    Qian, Y.
    Durkee, B. Y.
    Pollom, E. L.
    King, M.
    Dudley, S. A.
    Shaffer, J. B.
    Chang, D. T.
    Gibbs, I. C.
    Goldhaber-Fiebert, J. D.
    Horst, K. C.
    CANCER RESEARCH, 2016, 76
  • [22] The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+Metastatic Breast Cancer (TBCRC 062)
    Parsons, Heather
    Ruddy, Kathryn
    Morganti, Stefania
    Smith, Karen
    Attaya, Victoria
    Kallfelz, Eliza
    DeMeo, Michelle
    LaScala, Jamie
    Mertz, Shirley
    Pollastro, Teri
    Spears, Patricia
    Brufsky, Adam
    Dang, Chau
    Dent, Susan
    Elkhanany, Ahmed
    Gwin, WIlliam
    O'Sullivan, Ciara
    Miller, Kathy
    Nunnery, Sara
    Walsh, Elaine
    Storniolo, Anna Maria
    Tolaney, Sara
    Tayob, Nabihah
    Wolff, Antonio
    Winer, Eric
    Rimawi, Mothaffar
    Krop, Ian
    Lin, Nancy
    CANCER RESEARCH, 2024, 84 (09)
  • [23] Updated Austrian treatment algorithm in HER2+metastatic breast cancer
    Bartsch, Rupert
    Gampenrieder, Simon Peter
    Rinnerthaler, Gabriel
    Petru, Edgar
    Egle, Daniel
    Petzer, Andreas
    Balic, Marija
    Pluschnig, Ursula
    Sliwa, Thamer
    Singer, Christian
    WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (1-2) : 63 - 72
  • [24] TRASTUZUMAB (T) TOLERABILITY AND ACTIVITY IN HER2+METASTATIC BREAST CANCER (MBC) PATIENTS (PTS) AGED ≥65 YEARS
    Bernardi, A.
    Zucchini, G.
    Rosati, M.
    Rubino, D.
    Quercia, S.
    Cacciari, N.
    Zamagni, C.
    Martoni, A. A.
    ANNALS OF ONCOLOGY, 2010, 21 : 102 - 102
  • [25] Epidemiology of HER2+metastatic breast cancer in Germany and France in 2019
    DeBusk, Kendra
    Schwartz, Naomi R. M.
    Dennett, Susan
    Lindegger, Nicolas
    Pulgar, Sonia
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 39 - 39
  • [26] S-1 in combination with CPT-11 plus trastuzumab for pretreated HER2+metastatic breast cancer
    Toh, U.
    Iwakuma, N.
    Mishima, M.
    Furukawa, M.
    Fujii, T.
    Ogo, E.
    Nakagawa, S.
    Tanaka, M.
    Akagi, Y.
    BREAST, 2015, 24 : S28 - S28
  • [27] HEALTH STATE UTILITY VALUES FOR HER2+METASTATIC BREAST CANCER
    Paracha, N.
    Thuresson, P.
    Ray, J.
    VALUE IN HEALTH, 2017, 20 (05) : A115 - A115
  • [28] Syngeneic mouse model of human HER2+metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus
    Taha, Zaid
    Crupi, Mathieu J. F.
    Alluqmani, Nouf
    Fareez, Faiha
    Ng, Kristy
    Sobh, Judy
    Lee, Emily
    Chen, Andrew
    Thomson, Max
    Spinelli, Marcus M.
    Ilkow, Carolina S.
    Bell, John C.
    Arulanandam, Rozanne
    Diallo, Jean-Simon
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [29] THE CHALLENGE OF VALUE-BASED PRICING IN COMBINATION THERAPY:THE CASE OF TRASTUZUMAB AND PERTUZUMAB IN HER2+METASTATIC BREAST CANCER
    Jiao, B.
    Garrison, L. P.
    VALUE IN HEALTH, 2020, 23 : S34 - S35
  • [30] The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+metastatic breast cancer
    Jiao, Boshen
    Garrison, Louis P., Jr.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 495 - 502
12345